Provided is the use of a pharmaceutically acceptable salt of eteplirsen in the treatment of Duchenne muscular dystrophy. The pharmaceutically acceptable salt of eteplirsen may be administered once weekly by intravenous infusion at a dose of 30 mg/kg or 50 mg/kg for more than 120 weeks.
